Skip to main content
. 2014 Aug 7;110:132–141. doi: 10.1016/j.antiviral.2014.07.013

Fig. 5.

Fig. 5

VNA and total IgG in brains and sera, viral copy number and the expression of κ-light chain mRNA in brains of immunocompetent mice treated with MCP-1 with or without VNA after infection with DRV. ICR mice (groups of 3) at the age of 4–6 weeks were infected i.m. with 10 IMLD50 DRV-Mexico and then treated with recombinant murine MCP-1 (25 μg/mouse, i.c.) and RABV-antibody negative (N) or positive serum (Ab) at 5 dpi. Mice were euthanized at 12, 24, 36, 48 h after the treatment) as well as at 10 dpi (indicated as D10) or survived at 15 dpi (indicated as D15). There is another group of one ICR mouse with only DRV infection and sacrificed at 10 dpi (DRV/D10). Both sera and brains from all groups were harvested for determination of VNA in brains (A) and in sera (B), total IgG in brains (C) and sera (D), viral genomic RNA copy number in brains (E) and the expression of κ-light chain mRNA in brains (F). Data are presented as mean values ± SEM. Asterisks indicate significant differences (p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001) between the corresponding time points of MCP-1 with N or Ab groups. ND: not done.